2-[(4,6-dimethylpyrimidin-2-yl)sulfanyl]-N-[5-(naphthalen-1-ylmethyl)-1,3-thiazol-2-yl]acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-[(4,6-dimethylpyrimidin-2-yl)sulfanyl]-N-[5-(naphthalen-1-ylmethyl)-1,3-thiazol-2-yl]acetamide
• 英文别名: 2-(4,6-dimethylpyrimidin-2-yl)sulfanyl-N-[5-(naphthalen-1-ylmethyl)-1,3-thiazol-2-yl]acetamide
• 化学式: C₂₂H₂₀N₄OS₂
• 分子量: 420.6
• InChiKey: MENNDDDTIIZDDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Expansion and differentiation of inner ear supporting cells and methods of use thereof
  申请人：Massachusetts Eye and Ear Infirmary

  公开号：US11466252B2

  公开（公告）日：2022-10-11

  This disclosure relates to methods for expanding inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) and differentiating inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) to inner ear hair cells (e.g., atonal homolog 1 (Atoh1)+ inner ear hair cells) and the use of the inner hear supporting cells and hair cells, e.g., for identifying candidate therapeutic compounds for the treatment of hearing loss and balance loss. Additionally, the methods described herein can be used in the treatment of a subject having hearing loss and balance loss that would benefit from increased proliferation and differentiation of inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells).

  本公开涉及扩增内耳支持细胞（如Lgr5+内耳支持细胞）和将内耳支持细胞（如Lgr5+内耳支持细胞）分化为内耳毛细胞（如阿托纳同源物1（Atoh1）+内耳毛细胞）的方法，以及内耳支持细胞和毛细胞的用途，如用于鉴定治疗听力损失和平衡损失的候选治疗化合物。此外，本文所述的方法还可用于治疗听力损失和平衡失调患者，这些患者将受益于内耳支持细胞（如Lgr5+内耳支持细胞）的增殖和分化。
• EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：EP3407901B1

  公开（公告）日：2021-07-21
• Expansion and Differentiation of Inner Ear Supporting Cells and Methods of Use Thereof
  申请人：Massachusetts Eye and Ear Infirmary

  公开号：US20190010449A1

  公开（公告）日：2019-01-10

  This disclosure relates to methods for expanding inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) and differentiating inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) to inner ear hair cells (e.g., atonal homolog 1 (Atoh1)+ inner ear hair cells) and the use of the inner hear supporting cells and hair cells, e.g., for identifying candidate therapeutic compounds for the treatment of hearing loss and balance loss. Additionally, the methods described herein can be used in the treatment of a subject having hearing loss and balance loss that would benefit from increased proliferation and differentiation of inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells).
• Methods of Treating PACS1 and PACS2 Syndromes
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20210290612A1

  公开（公告）日：2021-09-23

  Methods are provided for treatment of PACS1 syndrome and PACS2 syndrome.
• SIRT2-ABLATED CHIMERIC T CELLS
  申请人：H. Lee Moffitt Cancer Center and Research Institute, Inc.

  公开号：US20220017863A1

  公开（公告）日：2022-01-20

  Disclosed herein are lymphocytes for use in adoptive cell transfer that have chemically- or genetically-inhibited Sirt2 expression. Also disclosed are methods of inhibiting or ablating Sirt2 expression in a T cell ex vivo. Also disclosed are methods of treating cancer in a subject that involves collecting lymphocytes, such as tumor infiltrating lymphocytes (TILs), from the subject, treating the lymphocytes ex vivo to inhibit Sirt2 expression, and transferring the modified lymphocytes back to the subject.